Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prospective Study of Rapamycin for the Treatment of SLE (Rapamune)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Andras Perl, MD, Ph.D, State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT00779194
First received: October 23, 2008
Last updated: October 12, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)